IL23A and psoriasis: For example, a systematic review found that ADA formation in psoriasis patients treated with IL-23 inhibitors had incidence rates of 4.1–14.7% with guselkumab, 141–31% with risankizumab and 6.51–18% with tildrakizumab [90].